GlassScriptPhysician profile
Brian Christopher Orcullo
NPI 1013639160
$5,379.29
in general payments reported to CMS, 2019-2025
24 companies · $963 in 2025
The $963 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,665 · 2023: $1,742 · 2024: $1,009 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364 · Travel and Lodging: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.16 |
| Travel and Lodging | $349.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,896.20 | 2022-2025 | Vanta Adaptivestim, Intellis Adaptivestim, Synchromedii |
| Relievant Medsystems, INC. | $990.16 | 2022-2023 | Intracept |
| Boston Scientific Corporation | $858.74 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Bionic Navigator |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $579.35 | 2022-2025 | Relistor |
| Curonix LLC | $172.56 | 2022-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Almatica Pharma LLC | $121.11 | 2022-2023 | Gralise |
| Abbott Laboratories | $119.42 | 2023-2024 | Proclaim, Eterna |
| Bioventus LLC | $78.30 | 2024-2025 | Durolane |
| Scilex Pharmaceuticals INC. | $67.41 | 2022-2024 | |
| Protega Pharmaceutials INC | $63.40 | 2023-2025 | Roxybond |
| Averitas Pharma INC. | $62.49 | 2023 | Qutenza |
| Amneal Pharmaceuticals LLC | $56.34 | 2023 | Lyvispah |
| Spr Therapeutics, INC | $53.89 | 2023 | Sprint Pns System |
| Abbvie INC. | $44.68 | 2023-2024 | |
| Globus Medical, INC. | $29.07 | 2025 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $25.16 | 2025 | Tonmya |
| Saluda Medical Americas, INC. | $25.00 | 2025 | Evoke |
| Si-Bone, INC. | $21.45 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.17 | 2023 | Horizant |
| Foundation Fusion Solutions, LLC | $20.17 | 2024 | |
| Valinor Pharma, LLC | $19.37 | 2024 | Movantik |
| Lundbeck LLC | $19.23 | 2023 | Vyepti |
| Nevro Corp. | $19.09 | 2023 | Senza |
| Masimo Corporation | $15.53 | 2023 | Patient Safetynet System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Orcullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.